Mazdutide (IBI362, LY3305677) is a revolutionary dual GLP-1 and glucagon receptor agonist that's transforming weight loss and type 2 diabetes management. With exceptional efficacy and a remarkable safety profile, it leads the pack in Phase 3 trials, delivering significant weight loss without the common gastrointestinal side effects.
Mechanism
Mazdutide's unique dual action engages both GLP-1 and glucagon receptors, leading to enhanced insulin secretion and reduced glucagon levels. This synergy not only curbs appetite but also ramps up energy expenditure, promoting healthier lipid metabolism and lowering hepatic fat synthesis. It's a comprehensive strategy for obesity management and achieving glycemic control.
Research
In the Phase 3 GLORY trial, participants taking Mazdutide experienced an impressive average weight loss of 14.01% with the 6 mg dose over 48 weeks, significantly outperforming Semaglutide in reducing liver fat accumulation. This highlights its potential for superior metabolic benefits and overall health improvements in individuals with type 2 diabetes.
Synergies
Mazdutide pairs seamlessly with other metabolic therapies and lifestyle changes, optimizing weight loss and metabolic health. Ben IQ tailors your approach by analyzing YOUR labs and goals to create the perfect stacking strategy.
Trade-Offs
While Mazdutide offers outstanding efficacy, it's essential to monitor individual responses over time. Each person's journey is unique, so your treatment plan should be guided by YOUR specific data.